Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis Said Considering Takeover in Biotech Sector

11/18/2021 | 04:06am EST


ę MT Newswires 2021
All news about NOVARTIS AG
01/20BAUSCH HEALTH BRIEF : He Will join Bausch + Lomb from Allergan/AbbVie; Prior to that, he w..
MT
01/20NOVARTIS AG : JP Morgan keeps a Sell rating
MD
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
AQ
01/18Novartis CEO Expects Worldwide Normalcy to COVID-19 By 2022-End
MT
01/18GLOBAL MARKETS LIVE : Toyota, Microsoft, Goldman Sachs, Alibaba, Boeing...
01/18Molecular Partners Shares Drop 14% After Novartis Deal
DJ
01/18Wall Street Set for Downbeat Open Amid Rising Treasury Yields
MT
01/18Health Care Stocks Retreat Pre-Bell Tuesday
MT
01/18Top Premarket Decliners
MT
01/18Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Develo..
MT
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 971 M - -
Net income 2021 24 212 M - -
Net Debt 2021 8 123 M - -
P/E ratio 2021 8,19x
Yield 2021 3,69%
Capitalization 199 B 199 B -
EV / Sales 2021 3,98x
EV / Sales 2022 3,83x
Nbr of Employees 108 000
Free-Float 85,7%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 88,75 $
Average target price 98,67 $
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG1.38%198 846
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833